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Abstract
Five-fluorouracil (5-FU) is a chemotherapeutic agent that is mainly metabolized
by the rate-limiting enzyme dihydropyrimidine dehydrogenase (DPD). The DPD
enzyme activity deficiency involves a wide range of severities. Previous studies
have demonstrated the effect of a DPYD single nucleotide polymorphism on 5-FU
efficacy and highlighted the importance of studying such genes for cancer treatment. Common polymorphisms of DPYD in European ancestry populations are
less frequently present in Koreans. DPD is also responsible for the conversion of
endogenous uracil (U) into dihydrouracil (DHU). We quantified U and DHU in
plasma samples of healthy male Korean subjects, and samples were classified into
two groups based on DHU/U ratio. The calculated DHU/U ratios ranged from
0.52 to 7.12, and the two groups were classified into the 10th percentile and 90th
percentile for untargeted metabolomics analysis using liquid chromatography-
quantitative time-of-flight-mass spectrometry. A total of 4440 compounds were
detected and filtered out based on a coefficient of variation below 30%. Our results
revealed that six metabolites differed significantly between the high activity group
and low activity group (false discovery rate q-value < 0.05). Uridine was significantly higher in the low DPD activity group and is a precursor of U involved in
pyrimidine metabolism; therefore, we speculated that DPD deficiency can influence uridine levels in plasma. Furthermore, the cutoff values for detecting DPD
deficient patients from previous studies were unsuitable for Koreans. Our metabolomics approach is the first study that reported the DHU/U ratio distribution in
healthy Korean subjects and identified a new biomarker of DPD deficiency.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe
5-fluorouracil toxicity. To predict DPD activity, DPYD genotyping and DPD phenotyping using dihydrouracil and uracil ratio were used.
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WHAT QUESTION DID THIS STUDY ADDRESS?
This study aimed to identify the distribution of DPD activity in a Korean population and explore new biomarkers of DPD activity using untargeted metabolomics.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study recognized different distributions of DPD activity between a Korean
population and populations of other ethnicities. The cutoff values for activity
deficiency based on other ethnic groups could not be considered for East Asian
populations, including Korean populations.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
This study indicated that a new cutoff value should be further validated to overcome the variability in DPD phenotyping in East Asian populations. The new
biomarker for DPD deficiency uridine has the potential for more feasible and
convenient prediction analysis.

I N T RO DU CT ION
Dihydropyrimidine dehydrogenase (DPD) is the rate-
limiting enzyme that catabolizes 5-fluorouracil (5-FU).1
DPD plays a pivotal role in that over 80% of 5-FU is degraded by DPD in the liver, and a deficiency in DPD activity causes severe toxicity.2 DPYD is a DPD encoding
gene, and its variant alleles are related to DPD activity.2
Previous studies have suggested DPYD single nucleotide
polymorphisms to predict drug toxicities prior to the
administration of drugs to patients who were heterozygous or homozygous for a mutant DPYD allele.2 In addition, the Clinical Pharmacogenetics Implementation
Consortium (CPIC) guidelines have updated the guided
dosing of fluoropyrimidine.3 The distinguished DPYD variant c.190511G>A (*2A) is recognized to have the strongest impact on DPD activity.4 DPYD*2A genotype-guided
dosing has improved the safety and cost savings of fluoropyrimidine therapy.5 However, common polymorphisms
of DPYD, such as DPYD*2A and DPYD*13 in European
ancestry populations and other populations, are less frequently present in East Asian populations.6,7 Considering
that common polymorphisms of DPYD*2A and DPYD*13
hardly exist in East Asian populations, two novel DPYD
genetic variants, −832 G>A and −131 C>A, were reported
in a previous study and have been associated with enzyme
activity in a Korean population.7 Individuals with higher
DPD enzyme activity possessed genetic variant, –832 G>A
and DPD enzyme activity was reduced in individuals with
genetic variant, −131 C>A.7
Over the years, diverse strategies for DPD phenotyping
methods have been studied and discussed for predicting
5-FU-induced toxicity.8 One of the methods to determine
DPD deficiency is measuring DPD enzyme activity in peripheral blood mononuclear cells (PBMCs).9 A previous

study showed DPD activity in PBMCs is highly correlated
with liver DPD activity in patients.10 Besides, it has high
sensitivity to distinguish enzyme activity; however, DPD
activity in PBMCs highly fluctuates in both healthy volunteers and patients.8,11 The DPD enzyme also catabolizes
endogenous uracil (U) and thymine (T) to dihydrouracil
(DHU) and dihydrothymine (DHT).12 Several studies have
been reported based on the knowledge that DPD deficiency perhaps decreases the metabolic ratio of U, which
results in a higher concentration of U in patients with severe toxicity of 5-FU.13–16 To predict the efficacy and toxicity of 5-FU, DPD phenotyping using the metabolic ratio
of U is useful to determine patients with DPD deficiency.14
The endogenous metabolic ratio of U in plasma showed
a correlation with the 5-FU plasma concentration and
clearance.15
Global metabolomics profiling is an omics technology
that provides information to understand individual variability in various physiological conditions and snapshots
of entire physiology associated with the outcome phenotype.17 More, metabolomics offers feasibility of biomarker
discovery that metabolites act an important role in biological system.18 Considering the low frequency of common DPYD polymorphism in the Korean population, the
metabolic ratio of U might be different between Korean
and other ethnicities, and a new biomarker would yield
the more feasible and practical application of DPD deficiency screening. Therefore, the aim of this study was to
evaluate the metabolic ratio of U as a predictive marker of
DPD enzyme activity in a Korean population and explore
a new biomarker of DPD activity deficiency using an untargeted metabolomics tool. To the best of our knowledge,
this is the first study analyzing the metabolic ratio of U in
a Korean population and provides a new marker of DPD
deficiency using untargeted metabolomics.
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M ET H O DS
Study design and sample collection
Healthy subject plasma was provided by the Blood
Bank in Seoul National University Hospital and stored
at −70°C until use. The study protocol was approved
by the Institutional Review Board of the Seoul National
University Hospital (study identification number: H-1608-
170-789). Subjects were enrolled from 2015 to 2016 and
gave written informed consent. The average age of healthy
subjects was 30 ± 2.3 years. A total of 511 samples collected in a fasted state from healthy Korean male subjects
were included for this targeted analysis. For untargeted
analysis, the 90th percentile and 10th percentile groups
consisted of 51 subjects according to their metabolic ratio
of U and classified into low and high DPD activity groups.
To clarify the results, quantitation of a significant marker
was performed using 507 out of 511 plasma samples. The
workflow of this study was summarized in Figure 1.

Targeted metabolomics analysis for
U and T
Sample preparation for U, DHU, T, and DHT
quantitation
Standard stock solutions of U, DHU, T, and DHT, internal
standard (IS), and quality controls (QCs) were prepared
separately and diluted with 50% methanol. Thymine-d4 was
used as the IS. The IS (50 ng/ml) was added to 300 µl of
plasma sample. Plasma proteins were precipitated with 1 ml

of ethyl acetate. The mixture was vortexed for 1 min and
centrifuged at 12,000 g for 10 min. Then, the supernatant
was evaporated under nitrogen gas. Dried samples were reconstituted using 100 µl of 50% methanol. Calibration curve
concentrations ranged from 2 to 650 ng/ml for U and from
1 to 650 ng/ml for T. For DHU and DHT, the calibration
concentrations ranged from 2 to 6500 ng/ml.

Sample preparation for uridine quantitation
Standard stock solutions of uridine, IS, and QCs were prepared separately and diluted with 50% methanol. Uridine-
2-13C-1,3-15N2 was used as the IS. The IS (1 µg/ml) was
added to 50 µl of plasma sample. Plasma proteins were
precipitated with 500 µl of acetonitrile. The mixture was
vortexed for 1 min and centrifuged at 14,000 g for 10 min.
Then, the supernatant was transferred to an autosampler
vial. Calibration curve concentrations ranged from 100 to
10,000 ng/ml for uridine.

Liquid chromatography and mass spectrometry
Mass spectrometric analyses were performed using an AB
SCIEX QTRAP 5500 instrument (AB SCIEX, Foster City,
CA, USA) coupled with an ultrahigh-performance liquid
chromatography (UPLC) instrument (Waters, Milford,
MA, USA). For U, T, DHU, and DHT quantification, one
microliter of reconstituted sample was injected directly
onto Synergi 4 µm Polar-RP 80 A LC column (150 ×
4.6 mm; Phenomenex, Torrance, CA, USA). The isocratic
mobile phase consisted of high-performance liquid chromatography (HPLC) grade water (solvent A) and acetonitrile (solvent B) at a flow rate of 0.6 ml/min. For uridine
quantification, one microliter of supernatant was injected
directly onto 2.1 mm × 100 mm ACQUITY 1.7 μm UPLC
BEH C18 Column (Waters, USA). The isocratic mobile
phase consisted of HPLC grade water with 0.1% formic
acid (solvent A) and methanol with 0.1% formic acid (solvent B) at a flow rate of 0.3 ml/min. Mass spectrometric
detection was conducted in negative electrospray ionization mode. Calibration curves were generated using linear regression after plotting the peak areas against the
analyte concentrations within a dynamic range.

Untargeted metabolomics analysis
Sample preparation
F I G U R E 1 Study work flow. DPD, dihydropyrimidine
dehydrogenase; FDR, false discovery rate; LC-MS-MS, liquid
chromatography tandem mass spectrometry

The 70 µl of plasma sample was mixed with 280 µl of
pre-chilled 1:1 acetonitrile/methanol (v/v) and vortexed
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briefly. The mixture was centrifuged at 14,000 g for
10 min, and then 300 µl of supernatant dried under nitrogen gas. Dried samples were reconstituted using 400 µl of
80% acetonitrile.

Liquid chromatography and mass spectrometry
Untargeted metabolomics was performed by a Waters
SYNAPT G2-S time of flight platform (Waters, USA). A
4 µl aliquot of each reconstituted sample was injected
into a Waters UPLC system with a 2.1 mm × 100 mm
ACQUITY 1.7 μm BEH HILIC column. The mobile
phase was composed of 0.1% formic acid (solvent A)
and methanol containing 0.1% formic acid (solvent B).
The gradient was as follows: 0–1.5 min, 99% B; 1.50–
11.50 min, 50% B; and the equilibrium time was 6.5 min.
Both positive and negative ionization modes were operated. Pooled QC replicates were analyzed with samples
for consistency and stability.

Data processing
Metabolomic data were imported into EZinfo 2.0 software (Umetrics, Umea, Sweden) for multivariate analysis.
Progenesis QI software (version 2.3; Nonlinear Dynamics,
Newcastle, UK) was used for peak alignment, peak picking, deconvolution, normalization, and statistical analysis. Peak alignment and peak picking was processed by
pooled QC replicates. Most suitable reference was selected
to normalize all detected ions. A quantitative abundance
ratio between the run and the reference run was calculated to normalize compounds. Metabolic features were
filtered with a coefficient of variation (CV) of abundance
greater than 30% in the QCs. Significantly different features were selected with a false discovery rate adjusted
p value (q-value) less than 0.05. The volcano plot was conducted with log2 transformed data using GraphPad Prism
software version 7.0 (GraphPad Software Inc., San Diego,
CA, USA).

RES ULT S
U and DHU quantification and distribution
Plasma samples from a total of 511 healthy subjects were
used for quantitation of U and DHU. The median and
mean DHU/U ratios were 2.14 and 2.26, respectively. The
median and mean DHT/T were 61.20 and 63.37, respectively (Figure S1). Our current data showed a weak correlation between the metabolic ratios of U and T, coinciding
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with those from a previous study in healthy controls and
patients with cancer (Figure S2).12 Samples were classified into high and low DPD activity groups according to
the distribution of the metabolic ratio, corresponding
to the 90th and 10th percentiles of metabolic ratio of U,
respectively (Figure 2). The 90th percentile metabolic
ratio of U ranged from 3.11 to 7.12. The 10th percentile
metabolic ratio of U ranged from 0.52 to 1.571 (Figure 2).
Both groups were subjected to untargeted metabolomics
analysis using liquid chromatography-quantitative time-
of-flight-mass spectrometry.

Plasma metabolic profiling using
untargeted metabolomics
Untargeted global profiling of plasma was performed for
samples in the 90th and 10th percentiles of the metabolic
ratio of U. In total, 4440 compounds were detected and
filtered out based on a CV below 30%. Principal component analysis displayed no clear separation between the
high DPD activity group and the low DPD activity group
(Figure 3a). Ions with a q-value less than 0.05 between the
two groups were selected. The volcano plot highlighted
six metabolites that differed significantly between the
high DPD activity group and the low DPD activity group
(q-value < 0.05; Figure 3b). One distinguishable marker
was identified as uridine using authentic compound
(Figure S3). However, the other five ions (m/z 419.3554,
249.9205, 855.5117, 864.5028, and 311.2943) were not
identified.

Depending on the metabolic ratio of U,
uridine levels showed changes in plasma
from healthy subjects
The uridine was significantly higher in the low DPD activity group than in the high activity group (Figure 4).
The concentration of uridine showed a weak correlation
with the calculated metabolic ratio of U and U concentrations (Figure S4). The plasma level of uridine showed
alterations between the 90th and 10th percentiles of the
metabolic ratio of U. Uridine is a precursor of U, and both
metabolites are involved in pyrimidine metabolism.19

DISCUSSION
To our knowledge, this is the first study to evaluate the
metabolic ratio of U in a Korean population. Although
some studies reported an association between the metabolic ratio of U and DPD activity,13,14 this study is the first
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F I G U R E 2 Distribution of DHU/U
ratio in 511 healthy subjects. The 90th
percentile and 10th percentile groups
consisted of 51 subjects. The dashed line
represents the threshold of each 90th
percentile and 10th percentile. DHU/U,
dihydrouracil/uracil

F I G U R E 3 Multivariate analysis of plasma metabolomic profiles. (a) Principal component analysis (PCA) unsupervised clustering plots
for the high DPD activity group (black square) and low DPD activity group (red circle). (b) The volcano plot shows t-test results of samples
from the high DPD activity group and low DPD activity group. Red dots are upregulated metabolites and blue dots are downregulated
metabolites. The dashed horizontal line reflects the filtering area (FDR adjusted p value < 0.05). DPD, dihydropyrimidine dehydrogenase;
FDR, false discovery rate

to address a new biomarker of DPD activity deficiency
using untargeted metabolomics. Our results indicated
the following: (i) in the Korean population, the metabolic
ratio of U indicating the prediction of 5-FU toxicity shows
dissimilar distribution with other populations; and (ii) our
untargeted approach identified a new biomarker of DPD
deficiency, uridine, in plasma.
To date, quantifying U and DHU is one of the DPD phenotyping methods for evaluating its activity.8 Several studies have suggested the metabolic ratio of U measurement

as a screening method for DPD deficiency.13,14,16,20 Based
on those studies, we categorized the low and high activity
groups of DPD according to the percentile of the metabolic
ratio of U (Figure 1). In healthy Korean male subjects, the
distribution of the metabolic ratio of U ranged from 0.52
to 7.12; the median was 2.14. This range is lower than a
previously reported range of 0.002 to 17.3, and a median
was of 7.3 in 252 French White patients with colorectal carcinoma.21 In addition, the metabolic ratio of U in healthy
volunteers was previously reported to be 2.3 to 28.9, and
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F I G U R E 4 Box plot of uridine. This plot represents the
concentration of uridine. A t-test was used for statistical evaluation.
* p value <0.0001

the median was 11.2.11 An interethnic difference in the
metabolic ratio of U may be present in various populations.
In previous studies, cutoff values were assumed for a
plasma ratio of 4.0 or 6.0 to predict if patients have severe 5-FU toxicity in other ethnic groups.14,16,20 A total of
501 of 511 (98%) samples in our Korean population had
a DPD deficiency using the cutoff value of 4.0 and 509 of
511 (99.6%) Korean population had DPD deficiency using
the cutoff value of 6.0. However, East Asians had lower
rates of toxicity induced by fluoropyrimidine containing
regimens than other populations.22,23 Our data indicated
that the cutoff value in a previous study with other races
may be inappropriate to predict whether Korean patients
will present severe toxicity. New cutoff values should be
further explored and validated in East Asian populations.
We speculated that DPD activity deficiency can lead
to the accumulation of uridine in pyrimidine metabolism
(Figure 5). Uridine homeostasis is regulated uridine phosphorylase, an enzyme that converts uridine to U.24 The
uridine level was elevated in the low activity group, which
showed that DPD deficiency affected the uridine catabolism pathway. Uridine homeostasis is linked to pyrimidine
metabolism.25 In a previous study, uridine levels showed
an association with the metabolic ratio of U in plasma level
and similar patterns with U.26 This result is consistent with
our results, which showed a weak correlation between
uridine and U and the metabolic ratio of U (Figure S4).
Although many studies have shown the effectiveness of
the metabolic ratio of U,13,14,20 from analytical perspectives,
single compound analysis is simpler and more feasible
than analysis of multiple compounds. Hence, uridine may
be a new predictive marker of DPD deficiency.
The main limitation of our study is the lack of evaluation of patient’s clinical outcomes and consideration of

F I G U R E 5 Uridine, uracil, and dihydrouracil in pyrimidine
metabolism. Metabolomic analysis indicated that DPD activity
deficiency can lead to the accumulation of uridine in pyrimidine
metabolism. DPD, dihydropyrimidine dehydrogenase; NADPH,
nicotinamide adenine dinucleotide phosphate

the DPYD genotype. Most studies have investigated the
metabolic ratio of U in patients with cancer to predict
toxicity related to a fluoropyrimidine or 5-FU.13,14,20 We
recognized the distribution of the metabolic ratio of U in
healthy Korean male subjects and divided low and high
DPD activity groups using the metabolic ratio of U based
on published studies. Additionally, there was the lack of
female subjects in our study. However, a previous study
showed no significant correlation between sex and DPD
activity; the distribution of healthy Korean male subjects
is well-represented.27 Nevertheless, this result is not the
gold standard to detect DPD enzyme activity, and further
studies should be conducted in patients who struggle with
severe toxicity related to 5-FU to confirm these findings.
In conclusion, this is the first large sample size study to
show different distributions of DPD activity using quantification of U, DHU, T, and DHT in a Korean population.
Beyond providing a range of metabolic ratios of U in a
Korean population to support further investigation of new
cutoff values, our study also explored a new biomarker,
uridine, and, consequently, measuring pretreatment
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uridine levels may provide a feasible strategy for predicting DPD deficiency.
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